Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab for Active Sight-Threatening Uveitis
NCT02911116Phase 2Completed
- Sponsor
- National Eye Institute
- Start
- Mar 2017
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ustekinumab in uveitis (2 cohorts), sponsored by National Eye Institute. Primary endpoint: Number of Participants Experiencing a Treatment Response at 16 weeks. Started Mar 2017; status: completed.
02
Drugs
ustekinumab
03
Conditions
uveitis
Beyond the preview
Go deeper on NCT02911116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02911116.